0. Hugh Salter az-tsc-karolinska@astrazeneca.com
AstraZeneca Translational Science Centre AZ-Karolinska Institutet Joint Research Program in Translational Science
Hugh Salter

1. AZ Translational Science Centre @ Karolinska Institutet
Hugh Salter
Head TSC
Carina Jägenstedt Bismut
Administrator
KS PET Centre
Ina Schuppe Koistinen
Biochemical Biom. Lab Head
Magnus Ivarsson
Neurophysiology
Lab Head
Lars Farde
PET Lab Head &
Clinical Director
Anna Bogstedt
Biomarker Assays
Eva Lindström Böö
PET Project Manager
Elin Åberg
EEG Scientist
Susanna Eketjäll
Biomarker Assays
Aurelija Jucaite
PET Clinical Scientist
Vacant
AZ Postdoc
Kina Höglund
Biomarker Discovery
Zsolt Cselenyi
PET Clinical Scientist
Maria Bhat
Biomarker Discovery
Magnus Schou
PET Radiochemist
Ying Sun
AZ Postdoc
Peter Johnström
PET Radiochemist
Anna Mattsson
AZ Postdoc
SciLifeLab

2. Finding the right patients – prodromal AD
Alzheimers disease
Hint of subgroup in mild AD with Solenuzemab
Finding the right patients – prodromal AD
Selection of patients at appropriate disease stage
Identifcation of prognostic markers + using these appropriately
Enabling simple/peripheral measurement of central effects

3. AZ TSC, joint research and the Neuroscience iMED
AZ Neuroscience Innovative Medicines
Cambridge US
Cambridge UK
Internal / external partners
CRO, Consultancies. Biotech, Academia
AZ Translational Science Centre, KI
KI/AZ Joint Research Program in Translational Science
11 joint research programs, in place Q [4 MUSD/yr]
Centrumbildning – CNS
JRC – Jan Hillert, Anna Wedell, Lars Klareskog,
Hugh Salter, Lars Farde, Ina Schuppe, Magnus Ivarsson
Steering group
Jan Andersson, Gunnar von Heijne,
Sofia Hober, Britt Skogseid,
Anders Ekblom
KI/AZ/UU/SU/KTH – SciLifeLab Research Program
10 research programs, inititating Q [10 MUSD/yr]

4. AZ-KI Translational Science Centre
Joint Research Committee
KI : Profs. Anna Wedell, Lars Klareskog, Jan Hillert
AZ : Hugh Salter, Ina Schuppe Koistinen, Lars Farde, Magnus Ivarsson
JRC is quorate when cochairs or their representatives are present
Budget approval
Approval of scientific reports / agreement on achievements
Conflict resolution (publications, IP)
Scope and mechanism for next funding call (2015)
Project governance
Scientific report once per year
Financial report once per year, yearly payment of budget to host institution – see instructions in information folder.
Program co-ordinator – Ina Schuppe Koistinen
Administration – Carina Jägenstedt Bismut

5. KI-AZ Translational Science Centre
Centre budget
Fixed component (6 MSEK / yr) – infrastructure
Rent, animal facilities
Workshops
Attendance of postdocs/students to AZ postdoc conferences
Central analysis staff????
Research component (24 MSEK / yr) – staff + consumables
Only 80% pre-allocated (4 yr projects, 5 yr funding)
Grants to PIs
What happens in 2015?
Competitive renewal of current programs
New grant call for additional 2 year programs

6. Platforms at the Science for Life Laboratories, Stockholm
A national resource centre for technology-driven bioscience
Genomics / 2nd generation sequencing
Proteomics
siRNA screening
Biosample immunoscreening (histo + biofluids)
High-resolution microscopy
Chemical biology
Bioinformatics
High content biology
from 2013
Drug discovery
Protein production
Structural biology
Genetic models

7. AZ-KI Joint Research Program in TS : 2013 Projects
Per-Johan Jakobsson
Medicine
Identification of sub-phenotypes and biomarkers in systemic autoimmune diseases
Sven-Erik Dahlén
IMM, CfA
New biomarker patterns for phenotyping of asthma, allergies and COPD
Mauro D'Amato
BioNut
Post-genomic applications in IBD: exploitation of genetic information toward improved diagnosis and therapy
Johan Björkegren
MBB
DNA-on/DNA-off—towards biomarkers predicting molecular disease states driving coronary artery disease in subgroups of patients
Ulf Andersson
CMM
Development of assays to quantify HMGB1 isoform levels as biomarkers for mode of cell death and clinical prognosis in drug-induced liver injury (DILI)
Henrik Grönberg
MEB
Circulating tumor DNA as a personalized biomarker for treatment prediction and disease monitoring in prostate and breast cancer
Jonas Bergh
Onc-Pat
Search and identification of therapy predictive markers in primary and metastatic breast cancer with focus on TORC1/2 inhibition and AZD8931 with long-term goals of individual prognostication and tailored therapy selections
Janne Lehtiö
OncPat
Immediate adaptation analysis for prediction of efficient combination therapy with Gefitinib
Roman Zubarev, Agneta Nordberg, Dag Aarsland
Discovery of diagnostic and prognostic biomarkers of preclinical Alzheimer’s disease by combining advanced proteomics, metabolomics and lipidomics analyses of blood plasma and cerebrospinal fluid
Sophie Erhardt
PhyPha
The pursuit of immune biomarkers in schizophrenia– tracking down pathophysiological mechanisms
Per Svenningsson
CNS
Biomarkers of early Parkinson´s disease
R&I
CVGI
Safety
Onco NS